Claims for Patent: 5,328,470

Summary for Patent: 5,328,470

Title:	Treatment of diseases by site-specific instillation of cells or site-specific transformation of cells and kits therefor
Abstract:	A method for the direct treatment towards the specific sites of a disease is disclosed. This method is based on the delivery of proteins by catheterization to discrete blood vessel segments using genetically modified or normal cells or other vector systems. Endothelial cells expressing recombinant therapeutic agent or diagnostic proteins are situated on the walls of the blood vessel or in the tissue perfused by the vessel in a patient. This technique, provides for the transfer of cells or vectors and expression of recombinant genes in vivo and allows the introduction of proteins of therapeutic or diagnostic value for the treatment of diseases.
Inventor(s):	Nabel; Elizabeth G. (Ann Arbor, MI), Nabel; Gary J. (Ann Arbor, MI)
Assignee:	The Regents of the University of Michigan (Ann Arbor, MI)
Application Number:	07/741,244
Patent Claims:	1. A kit for treating a disease in a patient in need thereof, comprising a catheter and a physiologically acceptable solution, wherein: (i) said catheter is adapted for insertion into a blood vessel and comprises a main catheter body having a balloon element, adapted to be inserted in said blood vessel and being expansible against the walls of said vessel so as to hold said main catheter body in place, and means carried by said main catheter body for delivering said solution into said blood vessel; (ii) said physiologically acceptable solution comprises DNA and at least one member selected from the group consisting of heparin, poly-L-lysine, polybrene, dextransulfate, a polycationic material, and bivalent antibodies. 2. The kit of claim 1, wherein said physiologically acceptable solution further comprises a growth factor. 3. A kit for treating a disease in a patient in need thereof, comprising (i) a catheter adapted for insertion into a blood vessel, comprising a main catheter body having a balloon element adapted to being inserted into said vessel and expansible against the walls of the said vessels so as to hold said main catheter body in place in said vessel and a means carried by said main catheter body for delivering a physiologically acceptable solution into said blood vessel; (ii) said physiologically acceptable solution which may contain an enzyme, mild detergent or lipid; and (iii) a means for causing a cell attached onto the walls of a vessel or in an organ or tissue in said patient to express an exogenous therapeutic agent protein, comprising a formulation adapted for delivery by said catheter for the transfer and uptake of RNA or DNA into said cell attached onto the walls of a vessel or in an organ or tissue in said patient. 4. The kit according to claim 3, wherein said DNA is antisense DNA. 5. The kit of claim 3, wherein said solution contains, as said enzyme, at least one member selected from the group consisting of dispase, trypsin, collagenase, papain, pepsin, chymotrypsin, and lipases. 6. The kit of claim 3, wherein said solution contains at least one member selected from the group consisting of Nonidet P-40, Triton X100, deoxycholate, and sodium dodecyl sulfate. 7. The kit of claim 3, wherein said main catheter body comprises two spaced balloon elements, adapted to be inserted in a blood vessel and both being expansible against the walls of the blood vessel, for providing a chamber in said blood vessel and so as to hold said main catheter body in place, and whereas said means for delivering a physiologically acceptable solution into said chamber is situated in between said balloon elements. 8. The kit of claim 3, wherein said means for delivering said solution into said blood vessel comprises a plurality of pore means. 9. The kit of claim 3, wherein said formulation comprises a retrovirus, a plasmid, a liposomal formulation, or a plasmid complex with a polycationic substance. 10. The kit of claim 3, wherein said formulation is a liposomal formulation.

Details for Patent 5,328,470

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Smith & Nephew, Inc.	SANTYL	collagenase	Ointment	101995	06/04/1965		2011-07-12